Allianz SE Makes New $213,000 Investment in IQVIA Holdings Inc. (NYSE:IQV)

Allianz SE acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,080 shares of the medical research company’s stock, valued at approximately $213,000.

Several other institutional investors and hedge funds have also modified their holdings of the company. Intech Investment Management LLC acquired a new stake in shares of IQVIA during the third quarter worth $223,000. Captrust Financial Advisors boosted its stake in IQVIA by 30.8% in the 3rd quarter. Captrust Financial Advisors now owns 8,188 shares of the medical research company’s stock worth $1,940,000 after buying an additional 1,927 shares during the last quarter. PDT Partners LLC purchased a new stake in IQVIA in the 3rd quarter valued at about $853,000. Point72 Hong Kong Ltd purchased a new position in shares of IQVIA during the 3rd quarter worth about $434,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of IQVIA in the third quarter worth approximately $504,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of IQV stock opened at $176.28 on Tuesday. The firm has a market cap of $31.08 billion, a P/E ratio of 23.50, a P/E/G ratio of 1.99 and a beta of 1.50. The firm has a fifty day moving average of $192.73 and a two-hundred day moving average of $205.61. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 1-year low of $169.37 and a 1-year high of $253.84.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on IQV. BTIG Research downgraded shares of IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th. Bank of America lowered their price target on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, December 13th. UBS Group cut their price objective on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Finally, Stifel Nicolaus decreased their target price on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday, February 7th. Five equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.